Immunome, Inc.
IMNM
$18.17
-$0.22-1.20%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.02M | 6.94M | 9.68M | 12.59M | 10.94M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.02M | 6.94M | 9.68M | 12.59M | 10.94M |
| Cost of Revenue | 186.80M | 177.29M | 174.41M | 162.41M | 151.05M |
| Gross Profit | -182.78M | -170.35M | -164.73M | -149.82M | -140.11M |
| SG&A Expenses | 46.03M | 43.77M | 42.12M | 40.70M | 37.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 232.82M | 221.05M | 216.53M | 203.12M | 188.69M |
| Operating Income | -228.81M | -214.11M | -206.85M | -190.53M | -177.75M |
| Income Before Tax | -224.59M | -212.39M | -222.74M | -212.39M | -205.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -224.59 | -212.39 | -222.74 | -212.39 | -205.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -224.59M | -212.39M | -222.74M | -212.39M | -205.11M |
| EBIT | -228.81M | -214.11M | -206.85M | -190.53M | -177.75M |
| EBITDA | -226.35M | -211.65M | -204.56M | -188.42M | -175.73M |
| EPS Basic | -2.36 | -2.41 | -2.95 | -3.08 | -3.19 |
| Normalized Basic EPS | -1.41 | -1.44 | -1.57 | -1.58 | -1.58 |
| EPS Diluted | -2.36 | -2.41 | -2.96 | -3.09 | -3.19 |
| Normalized Diluted EPS | -1.41 | -1.44 | -1.57 | -1.58 | -1.58 |
| Average Basic Shares Outstanding | 383.04M | 349.31M | 317.22M | 289.47M | 262.39M |
| Average Diluted Shares Outstanding | 383.04M | 349.31M | 317.22M | 289.47M | 262.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |